Focus:
President Donald Trump stated the chances of reaching a deal before the next funding lapse are “less than 50–50” and another shutdown is “certainly an option”.
Expert speakers at this year’s JPM Healthcare Conference disagreed in their optimism for capital markets and M&A in 2019.
Research from pre-clinical and clinical studies has shown that checkpoint inhibition can be a crucial aspect of tumour immune evasion and systemic immune suppression.
GlobalData analysed the number of terminated oncology clinical trials with industry sponsors and a start date between January 1, 2013 and December 31, 2017.
In this issue: Knock on effects of the Valsartan recall, the future of AI in healthcare, the history of the Petri dish, and much more.
Researchers are coming under increasing pressure to develop therapeutics that enable patients to live longer and in good health.
Imbruvica, which was granted orphan drug designation by the FDA for the treatment of pancreatic cancer in 2017, now faces a setback in its label expansion plans in this area...
The migraine market had a landmark year in 2018, seeing the launch of three calcitonin gene-related peptide (CGRP) antagonists, a highly anticipated new class of drugs given these are specifically...
Spinal Muscular Atrophy (SMA) is a disease caused by a defective SMN gene, which leads to a lack of survival motor neuron (SMN) protein, which is important for the development...
Pharming Group is weighing other routes of administration and doses for Ruconest in response to an FDA Complete Response Letter received for the prophylaxis hereditary angioedema indication.
